Accolade Q2 2025 Earnings Report
Key Takeaways
Accolade reported revenue of $106.4 million and a net loss of $23.9 million for the fiscal second quarter ended August 31, 2024. The company is focused on delivering Adjusted EBITDA profitability and positive cash flow for the full fiscal year 2025.
Accolade is positioned to deliver its first full year of Adjusted EBITDA profitability and positive cash flow in fiscal year 2025.
The company's business model and strategy are designed to improve the lives of millions of people and their families.
Accolade is focused on solving the Physician Gap through a physician-led advocacy approach.
Net cash position improved by more than $20 million compared to convertible debt in the past year.
Accolade
Accolade
Forward Guidance
Accolade provides forward-looking guidance on revenue and Adjusted EBITDA. For the fiscal third quarter ending November 30, 2024, the company expects revenue between $104 million and $107 million and Adjusted EBITDA loss between $3 million and $5 million. For the fiscal year ending February 28, 2025, the company expects revenue between $460 million and $475 million and Adjusted EBITDA between $15 million and $20 million.
Positive Outlook
- Revenue between $104 million and $107 million for the fiscal third quarter ending November 30, 2024.
- Adjusted EBITDA loss between $3 million and $5 million for the fiscal third quarter ending November 30, 2024.
- Revenue between $460 million and $475 million for the fiscal year ending February 28, 2025.
- Adjusted EBITDA between $15 million and $20 million for the fiscal year ending February 28, 2025.